Hu Yu, Ye Zhen, She Yingqi, Li Linzhen, Wu Mingquan, Qin Kaihua, Li Yuzheng, He Haiqing, Hu Zhipeng, Yang Maoyi, Lu Fating, Ye Qiaobo
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2022 Mar 7;13:844961. doi: 10.3389/fphar.2022.844961. eCollection 2022.
The combination of probiotics and traditional Chinese medicine (TCM) is a prospective therapy for ulcerative colitis (UC), and its efficacy and safety need to be urgently evaluated. This study aims to comprehensively assess the efficacy and safety of probiotics combined with TCM for the treatment of UC. The Pubmed, EMBASE, Cochrane library, China Academic Journals (CNKI), Wan-fang database, Chinese biomedical literature service system (CBM), and Chinese Science and Technology Journals (CQVIP) were searched. Subgroup analysis were designed in accordance with different control drugs, treatment courses, and types of probiotics. The Review Manager software (version 5.4.1) was utilized for statistical analysis. 14 original studies containing 1,154 patients were analyzed and showed that probiotics with TCM was more effective than 5-aminosalicylic acid (5-ASA), probiotics or TCM used individually. Moreover, probiotics combined with TCM could inhibit the intestinal inflammation, reduce the recurrence rate and the incidence of adverse events. The subgroup analysis showed that a mixture of different probiotics was more effective than a single strain. It is suggested that probiotics combined with TCM could effectively control clinical symptoms, inhibit intestinal inflammatory response, and finally slow down the disease progress and reduce the disease recurrence with less adverse events. The mixture of different probiotics used in conjunction with individually tailored TCM is a potential clinical strategy for UC.
益生菌与中药联合应用是溃疡性结肠炎(UC)的一种前瞻性治疗方法,其疗效和安全性亟待评估。本研究旨在全面评估益生菌联合中药治疗UC的疗效和安全性。检索了Pubmed、EMBASE、Cochrane图书馆、中国学术期刊(CNKI)、万方数据库、中国生物医学文献服务系统(CBM)和中国科技期刊(CQVIP)。根据不同的对照药物、疗程和益生菌类型进行亚组分析。使用Review Manager软件(版本5.4.1)进行统计分析。分析了14项包含1154例患者的原始研究,结果显示益生菌联合中药比单独使用5-氨基水杨酸(5-ASA)、益生菌或中药更有效。此外,益生菌联合中药可抑制肠道炎症,降低复发率和不良事件发生率。亚组分析表明,不同益生菌的混合物比单一菌株更有效。提示益生菌联合中药可有效控制临床症状,抑制肠道炎症反应,最终减缓疾病进展,减少疾病复发,且不良事件较少。将不同益生菌混合物与个体化定制的中药联合使用是UC潜在的临床策略。